Hsu et al used the TriNetX platform to study the association between semaglutide use and the incidence of NAION and found that it was associated with an increased risk in patients with diabetes at the 2-, 3-, and 4-year timepoints but not within 1 year of GLP-1 RA initiation
Diabetologia 50 , 806813 (2007)
Ready to look like yourself again
At the conference, you are shown slides like this one, with the subtle hint of spiritual manipulation
4 This type of medication was approved by the FDA in 2005 and is generally an injectable delivered in the fatty tissue present just under the skin.4 GLP-1 agonists are prescribed by a doctor who may decide that they are appropriate for an individual based on their specific needs
So anything that can help to regulate blood sugar and also lead to meaningful weight loss can truly help to protect these patients long-term from those conditions, Dr